News

Privo Technologies Successfully Completes Phase 1/2 Study of PRV211 Intraoperative Chemotherapy for Head and Neck Cancer Patients Novel Surgical Innovation Demonstrates Excellent Safety Profile with Potential to Reduce Tumor Recurrence

'Peter Goldberg'2026-01-26T14:48:38+00:00

BOSTON, January 23, 2026  – Privo Technologies, Inc. today announced the successful completion of its Phase 1/2 clinical evaluation of PRV211, a first-in-class intraoperative chemotherapy patch for head and neck cancer patients. The study demonstrated excellent safety outcomes across all...

Privo Technologies Begins Dosing PRV131 in Arm 3 Of Clinical Study CLN-004, A First-In-Class Cisplatin Intratumoral Injectable Targeting Oral Cavity Cancer

'Peter Goldberg'2025-12-10T15:57:38+00:00

Key Highlights: First-in-human milestone: The inaugural patient has been dosed with PRV131. Precise, localized delivery: Built on Privo’s PRV Platform technology, PRV131 delivers high concentrations of cisplatin directly to tumors, while minimizing systemic exposure. Boston, MA — December 10, 2025...

PRV111, in Development as the First Non-Surgical Therapy for Early-Stage Non-Invasive Oral Cancer and High-Grade Dysplasias, Meets Its Primary Efficacy Endpoint in Ongoing Phase 2/3 Trial

'Peter Goldberg'2025-12-08T16:14:13+00:00

Key Highlights: 92% complete response (CR) rate: Eleven of twelve evaluable patients achieved a centrally confirmed pathologic CR following a single cycle of PRV111; the remaining patient was down-staged from high-grade to low-grade dysplasia. All patients avoided surgery: PRV111 cleared...

Privo Technologies Completes Phase 2 Run-In in PRV111 Oral Cancer Trial, Highlighting Potential to Spare Patients from Surgery

'Peter Goldberg'2025-12-08T16:15:12+00:00

Privo Technologies, Inc.  a leader in localized cancer therapies, today announced the completion of enrollment in Arm 1 of the Phase 2 run-in portion of its ongoing Phase 2/3 clinical trial (CLN-004) evaluating PRV111, a nano-engineered chemotherapy patch designed to...

Privo Technologies Inc. Expands CLN-004 Clinical Trial Across Leading U.S. Cancer Centers

'Peter Goldberg'2025-12-08T16:15:46+00:00

Privo Technologies, Inc., a clinical-stage biopharmaceutical company pioneering nanotechnology-based cancer therapies, is thrilled to announce the activation of multiple premier clinical sites across the United States for its ongoing CLN-004 trial. This Phase 2/3, open-label, two-arm study is evaluating the...

Privo Technologies Inc. Announces the Launch of BeneVet Oncology: Advancing Companion Animal Health Through Innovation

'Peter Goldberg'2025-12-08T16:16:21+00:00

Privo Technologies Inc., a pioneering biopharmaceutical company known for its innovative approach to drug delivery and cancer treatment, is proud to announce the launch of BeneVet Oncology, a new subsidiary dedicated to improving the health and well-being of companion animals....

Privo Technologies Receives $4.5M Funding from National Cancer Institute for Phase 3 Clinical Trial of Innovative Oral Cancer Treatment

'Peter Goldberg'2025-12-08T16:16:51+00:00

  Privo Technologies is proud to announce the receipt of $4.5 million in funding from the National Cancer Institute to support our pivotal Phase 3 clinical trial for a groundbreaking nanotechnology-based treatment targeting carcinoma in situ of the oral cavity (Stage...

Privo Technologies, Inc. Receives IRB Approval for PRV211- Intraoperative Chemotherapy Treatment for Solid Tumors

'Peter Goldberg'2025-12-09T21:16:18+00:00

Privo Technologies, Inc. is pleased to announce that it has received IRB approval for its CLN-004 study from WCG IRB.  CLN-004 is a Phase 1/2, open-label, safety and efficacy study accessing the tolerability, anti-tumor effects, systemic exposure, and device...

Privo Technologies, Inc. Awarded $2M Direct-to-Phase II Contract from the National Cancer Institute for PRV311 Treatment of Cervical Cancer

'Peter Goldberg'2025-12-09T21:15:52+00:00

PEABODY, Mass., Sept. 9, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo", "the Company") announced today that it has been awarded a $2M Direct-to-Phase II SBIR Contract from the National Cancer Institute (NCI), part of the National Institutes of Health. The contract will be used...

Forbes Article “Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems”

'Peter Goldberg'2025-12-09T21:22:09+00:00

Privo is excited to share the recent Forbes article titled, "Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems" written by one of our manuscript authors, Alex Zhavoronkov, PhD that highlights our nanoengineered PRV Platform. ...